Tgfß inhibitor and prodrugs
AssigneesFundació Institut de Recerca Biomèdica (IRB Barcelona), Institució Catalana De Recerca I Estudis AvançAts, Universitat De Barcelona
InventorsDaniele TAURIELLO, Daniel BYROM, Joan Antoni MATARÍN MORALES, Eduard BATLLE GÓMEZ, Antoni RIERA ESCALÉ
Life of this patent
Estimating the term…
Abstract
A compound of formula I with improved TGFβ signaling pathway inhibitory activity, improved therapeutic efficacy and improved toxicity profile, as well as two prodrugs thereof are disclosed. Compositions comprising said TGFβ signaling pathway inhibitor and prodrugs thereof are also disclosed. Additionally, present invention discloses said compound of formula I and prodrugs thereof for use in a method of treating diseases responsive to TGFβ signaling pathway inhibition.
Claims28
A compound of formula (I), or a pharmaceutical salt, or a pharmaceutically acceptable solvate thereof:
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.